uniQure Faces US Securities Lawsuit
Amsterdam, Monday 2 March 2026
Amsterdam’s uniQure N.V. is facing a securities class action by DJS Law Group, spotlighting the growing legal challenges for Benelux firms listed in the United States. The class period is between 24 September 2025 and 31 October 2025.
Regulatory Disclosures Under Fire
The legal complaint lodged by DJS Law Group centres on allegations that uniQure made false and misleading statements regarding the company’s clinical progress, specifically concerning its Pivotal Study design and the comparison to the ENROLL-HD data set [1]. According to the lawsuit, these research parameters failed to secure full FDA approval, a critical stumbling block in the company’s lab-to-market transition [1]. The plaintiffs argue that uniQure materially understated the risk that its Biologics License Application (BLA) would face significant delays due to the FDA’s requirement for additional studies, thereby misleading shareholders about the therapy’s commercial timeline [1].
Broader Litigation Landscape
This securities class action is indicative of a wider trend of intensified scrutiny on corporate disclosures within the US markets. DJS Law Group is simultaneously pursuing a class action against Kyndryl Holdings, Inc., alleging that the technology infrastructure company operated with deficient internal controls and misstated financial statements between August 2024 and February 2026 [2]. While the Kyndryl case focuses on financial reporting governance, the action against uniQure highlights the specific volatility faced by the life sciences sector, where regulatory milestones are often the primary drivers of valuation and investor risk [1][2].
Timeline for Investor Action
Investors seeking to participate in the litigation must adhere to strict procedural deadlines. Shareholders who purchased uniQure stock during the class period—from 24 September 2025 to 31 October 2025—have until 13 April 2026 to request appointment as a lead plaintiff [1]. This date coincides with the deadline for the Kyndryl lawsuit, marking a significant period of activity for the litigation firm [1][2]. It is important to note that appointment as a lead plaintiff is not a prerequisite for sharing in any potential financial recovery [1].